Broc S. Kelley, Cibele B. Carroll, John M. Hampton, Margaret R. Walker, Syed Nabeel Zafar, Dana Hayden, Andrea Schiefelbein, Roberto J. Vidri, Bret Benally Thompson, Noelle K. LoConte
{"title":"美国印第安人/阿拉斯加原住民直肠癌的差异","authors":"Broc S. Kelley, Cibele B. Carroll, John M. Hampton, Margaret R. Walker, Syed Nabeel Zafar, Dana Hayden, Andrea Schiefelbein, Roberto J. Vidri, Bret Benally Thompson, Noelle K. LoConte","doi":"10.1002/cam4.70892","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Purpose</h3>\n \n <p>Recent work noted lower overall survival (OS) in American Indian/Alaskan Native (AI/AN) individuals diagnosed with colon cancer compared with non-Hispanic White (NHW) individuals. Rectal cancer demographic profiles at diagnosis and survival outcomes have not been reported. We sought to identify differences in rectal cancer diagnosis and outcomes between AI/AN and White populations.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>White and AI/AN patients aged 18 or older, diagnosed between 2004 and 2020 with rectal adenocarcinoma were identified within the National Cancer Database (NCDB). Unadjusted and adjusted analyses were used to evaluate demographic and clinical standardized differences (stddiff) between AI/AN and White patients. Survival analyses of those diagnosed with locally advanced rectal cancer (Stage II/III) were performed using the Kaplan–Meier methods and multivariate Cox-proportional hazards modeling.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>176,341 eligible cases were identified: 0.6% were AI/AN (<i>N</i> = 992) and 99.4% White (<i>N</i> = 175,349). Compared to the White population, AI/AN patients were younger at diagnosis (mean age 59.9 vs. 64.5 years; stddiff = 0.36) and had more advanced stage disease (44.8% vs. 43.7%; stddiff = 0.15). A higher percentage of AI/AN resided in the areas of the lowest median income (35.5% vs. 15.1%; stddiff = 0.62) per zip code, rural (9.9% vs. 2.2%; stddiff = 0.65), and used Medicaid as their primary payor (14.3% vs. 6.2%; stddiff = 0.63). Adjusted analyses suggest the AI/AN group has an increased hazard of death compared with the White population (HR, 1.14; 95% CI, 1.05–1.25; <i>p</i> = 0.003).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>AI/AN patients with rectal cancer have a younger age and a more advanced stage at diagnosis. AI/AN race is associated with lower OS compared to White patients in multivariable analyses. Future efforts should focus on increasing colorectal cancer screening and access to treatment for AI/AN populations in an attempt to improve survival outcomes.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 8","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70892","citationCount":"0","resultStr":"{\"title\":\"Rectal Cancer Disparities Among the American Indian/Alaskan Native Populations\",\"authors\":\"Broc S. Kelley, Cibele B. Carroll, John M. Hampton, Margaret R. Walker, Syed Nabeel Zafar, Dana Hayden, Andrea Schiefelbein, Roberto J. Vidri, Bret Benally Thompson, Noelle K. LoConte\",\"doi\":\"10.1002/cam4.70892\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Purpose</h3>\\n \\n <p>Recent work noted lower overall survival (OS) in American Indian/Alaskan Native (AI/AN) individuals diagnosed with colon cancer compared with non-Hispanic White (NHW) individuals. Rectal cancer demographic profiles at diagnosis and survival outcomes have not been reported. We sought to identify differences in rectal cancer diagnosis and outcomes between AI/AN and White populations.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>White and AI/AN patients aged 18 or older, diagnosed between 2004 and 2020 with rectal adenocarcinoma were identified within the National Cancer Database (NCDB). Unadjusted and adjusted analyses were used to evaluate demographic and clinical standardized differences (stddiff) between AI/AN and White patients. Survival analyses of those diagnosed with locally advanced rectal cancer (Stage II/III) were performed using the Kaplan–Meier methods and multivariate Cox-proportional hazards modeling.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>176,341 eligible cases were identified: 0.6% were AI/AN (<i>N</i> = 992) and 99.4% White (<i>N</i> = 175,349). Compared to the White population, AI/AN patients were younger at diagnosis (mean age 59.9 vs. 64.5 years; stddiff = 0.36) and had more advanced stage disease (44.8% vs. 43.7%; stddiff = 0.15). A higher percentage of AI/AN resided in the areas of the lowest median income (35.5% vs. 15.1%; stddiff = 0.62) per zip code, rural (9.9% vs. 2.2%; stddiff = 0.65), and used Medicaid as their primary payor (14.3% vs. 6.2%; stddiff = 0.63). Adjusted analyses suggest the AI/AN group has an increased hazard of death compared with the White population (HR, 1.14; 95% CI, 1.05–1.25; <i>p</i> = 0.003).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>AI/AN patients with rectal cancer have a younger age and a more advanced stage at diagnosis. AI/AN race is associated with lower OS compared to White patients in multivariable analyses. Future efforts should focus on increasing colorectal cancer screening and access to treatment for AI/AN populations in an attempt to improve survival outcomes.</p>\\n </section>\\n </div>\",\"PeriodicalId\":139,\"journal\":{\"name\":\"Cancer Medicine\",\"volume\":\"14 8\",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-04-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70892\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70892\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70892","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
最近的研究表明,与非西班牙裔白人(NHW)相比,美国印第安人/阿拉斯加原住民(AI/AN)被诊断患有结肠癌的个体的总生存率(OS)较低。直肠癌的诊断和生存结果的人口统计资料尚未报道。我们试图确定AI/AN和白人人群在直肠癌诊断和预后方面的差异。方法在国家癌症数据库(NCDB)中确定2004年至2020年间诊断为直肠腺癌的18岁及以上的白人和AI/AN患者。采用未调整和调整分析来评估AI/AN和White患者之间的人口统计学和临床标准化差异(stddiff)。使用Kaplan-Meier方法和多变量cox -比例风险模型对诊断为局部晚期直肠癌(II/III期)的患者进行生存分析。结果共检出符合条件的病例176,341例,其中AI/AN占0.6% (N = 992), White占99.4% (N = 175,349)。与白人人群相比,AI/AN患者在诊断时更年轻(平均年龄59.9岁对64.5岁;Stddiff = 0.36),并且有更多的晚期疾病(44.8% vs. 43.7%;stddiff = 0.15)。居住在收入中位数最低地区的AI/AN比例较高(35.5%对15.1%;Stddiff = 0.62),农村地区(9.9% vs. 2.2%;stddiff = 0.65),并将医疗补助作为主要支付者(14.3% vs. 6.2%;stddiff = 0.63)。调整后的分析表明,与白人人群相比,AI/AN组的死亡风险增加(HR, 1.14;95% ci, 1.05-1.25;p = 0.003)。结论AI/AN合并直肠癌患者年龄较轻,诊断阶段较晚。在多变量分析中,与白人患者相比,AI/AN种族与较低的OS相关。未来的努力应集中在增加AI/AN人群的结直肠癌筛查和获得治疗,以改善生存结果。
Rectal Cancer Disparities Among the American Indian/Alaskan Native Populations
Purpose
Recent work noted lower overall survival (OS) in American Indian/Alaskan Native (AI/AN) individuals diagnosed with colon cancer compared with non-Hispanic White (NHW) individuals. Rectal cancer demographic profiles at diagnosis and survival outcomes have not been reported. We sought to identify differences in rectal cancer diagnosis and outcomes between AI/AN and White populations.
Methods
White and AI/AN patients aged 18 or older, diagnosed between 2004 and 2020 with rectal adenocarcinoma were identified within the National Cancer Database (NCDB). Unadjusted and adjusted analyses were used to evaluate demographic and clinical standardized differences (stddiff) between AI/AN and White patients. Survival analyses of those diagnosed with locally advanced rectal cancer (Stage II/III) were performed using the Kaplan–Meier methods and multivariate Cox-proportional hazards modeling.
Results
176,341 eligible cases were identified: 0.6% were AI/AN (N = 992) and 99.4% White (N = 175,349). Compared to the White population, AI/AN patients were younger at diagnosis (mean age 59.9 vs. 64.5 years; stddiff = 0.36) and had more advanced stage disease (44.8% vs. 43.7%; stddiff = 0.15). A higher percentage of AI/AN resided in the areas of the lowest median income (35.5% vs. 15.1%; stddiff = 0.62) per zip code, rural (9.9% vs. 2.2%; stddiff = 0.65), and used Medicaid as their primary payor (14.3% vs. 6.2%; stddiff = 0.63). Adjusted analyses suggest the AI/AN group has an increased hazard of death compared with the White population (HR, 1.14; 95% CI, 1.05–1.25; p = 0.003).
Conclusions
AI/AN patients with rectal cancer have a younger age and a more advanced stage at diagnosis. AI/AN race is associated with lower OS compared to White patients in multivariable analyses. Future efforts should focus on increasing colorectal cancer screening and access to treatment for AI/AN populations in an attempt to improve survival outcomes.
期刊介绍:
Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas:
Clinical Cancer Research
Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations
Cancer Biology:
Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery.
Cancer Prevention:
Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach.
Bioinformatics:
Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers.
Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.